- Home
- SEVN vs SERA Comparison
SEVN vs SERA Comparison
Compare SEVN & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEVN
- SERA
- Stock Information
- Founded
- SEVN 1986
- SERA 2008
- Country
- SEVN United States
- SERA United States
- Employees
- SEVN N/A
- SERA N/A
- Industry
- SEVN Real Estate Investment Trusts
- SERA Precision Instruments
- Sector
- SEVN Real Estate
- SERA Health Care
- Exchange
- SEVN Nasdaq
- SERA Nasdaq
- Market Cap
- SEVN 198.5M
- SERA 208.7M
- IPO Year
- SEVN N/A
- SERA 2021
- Fundamental
- Price
- SEVN $13.26
- SERA $6.42
- Analyst Decision
- SEVN Strong Buy
- SERA
- Analyst Count
- SEVN 3
- SERA 0
- Target Price
- SEVN $14.50
- SERA N/A
- AVG Volume (30 Days)
- SEVN 51.1K
- SERA 153.6K
- Earning Date
- SEVN 02-18-2025
- SERA 11-06-2024
- Dividend Yield
- SEVN 10.56%
- SERA N/A
- EPS Growth
- SEVN N/A
- SERA N/A
- EPS
- SEVN 1.28
- SERA N/A
- Revenue
- SEVN $30,401,000.00
- SERA $94,000.00
- Revenue This Year
- SEVN N/A
- SERA N/A
- Revenue Next Year
- SEVN N/A
- SERA $4,471.43
- P/E Ratio
- SEVN $10.36
- SERA N/A
- Revenue Growth
- SEVN N/A
- SERA N/A
- 52 Week Low
- SEVN $11.23
- SERA $4.98
- 52 Week High
- SEVN $14.66
- SERA $12.36
- Technical
- Relative Strength Index (RSI)
- SEVN 57.52
- SERA 37.74
- Support Level
- SEVN $12.63
- SERA $6.03
- Resistance Level
- SEVN $12.75
- SERA $6.83
- Average True Range (ATR)
- SEVN 0.39
- SERA 0.59
- MACD
- SEVN 0.05
- SERA -0.22
- Stochastic Oscillator
- SEVN 86.53
- SERA 14.44
About SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.